UK markets closed

Immuneering Corporation (IMRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.5100-0.1800 (-10.65%)
At close: 04:00PM EDT
1.5298 +0.02 (+1.31%)
After hours: 07:45PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Immuneering to Present at the Jefferies Global Healthcare Conference

    CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will b

  • GlobeNewswire

    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

    - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Ei

  • Simply Wall St.

    We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...